Plasticity of T helper cell differentiation

T辅助细胞分化的可塑性

基本信息

项目摘要

DESCRIPTION (provided by applicant): For protection against a wide array of diverse pathogens, T cells acquire distinct effector functions in response to each infection. For CD4+ T cells, these effector functions are characterized by the predominant cytokines produced by the effector cells. To date, five different subsets of CD4+ effector T cells have been described, and can be generated from na¿ve CD4+ precursors under controlled stimulation conditions. Similar subsets of functionally distinct CD8+ effector T cells have also been described. While early work in this area indicated that effector T cell differentiation was comparable to the terminal differentiation processes that occur during ontogeny, recent evidence indicates that T cell effector subsets are more plastic in their differentiation status. Not only do some T cells exhibit characteristics of more than one effector lineage at the same time, but additional instances of CD4+ and CD8+ effector T cells acquiring new cytokine profiles over the course of a response have also been observed. For instance, under certain conditions, CD4+ Th17 cells will acquire the capacity to produce IFNgamma, and Th1 cells will become IL-21-secreting Tfh cells. These data suggest that T cell responses can evolve over time, leading to alterations in the effector functions that predominate at different stages of an immune response. Importantly, this process is likely to play a key role in the evolution of autoimmune responses and may also contribute to the pathogenesis of chronic inflammatory diseases. We hypothesize that the transcriptional repressor, Blimp-1, is a critical regulator of T cell plasticity. Blimp-1 is upregulated in activatd CD4+ and CD8+ T cells by a specific subset of cytokines, including IL-2, IL-12, and IL- 4; thus, Blimp-1 is expressed in CD4+ effector Th1 and Th2, but not Th17, cells, as well as in Type I effector CD8+ T cells. We find that Th1 cells generated from Blimp-1-deficient na¿ve CD4+ T cells acquire a multi- lineage molecular program, expressing both Th1- and Th17-specific genes; a similar change in gene expression is seen in Blimp-1-deficient CD8+ T cells following LCMV infection. These data suggest that Blimp- 1 normally functions to repress Th17 and Tc17 differentiation, and further, may be required for effector cells to maintain a highly polarized Typ I subset identity. To test this hypothesis, we will first examine the molecular regulation of Blimp 1 transcription by distinct cytokines to determine the pattern of Blimp-1 expression at different stages of the immune response. We will then determine whether graded expression of Blimp-1 and/or Bcl-6 regulate Type I versus Type 17 effector cell differentiation during the development of a Th17-dependent autoimmune disease and during virus infection. Finally, we will determine whether persistent Blimp-1 expression is required to maintain Type I lineage identity, and whether conditional deletion of Blimp-1 in effector T cells alters their effector functions, and promotes their ability to induce autoimmunity. Together, these studies will determine whether the magnitude and duration of Blimp-1 expression are critical in the maintenance of T cell differentiation states, and whether alterations in Blimp-1 expression during an immune response contribute to the plasticity of effector functions. These data will provide important insights into the mechanisms contributing to autoimmune and other diseases caused by pathogenic T cell responses.
描述(由申请人提供):为了保护不同种类的病原体,T细胞对每一种感染都有不同的效应器功能。对于CD4+T细胞,这些效应器功能的特征是由效应器细胞产生的主要细胞因子。到目前为止,已经描述了五种不同的CD4+效应T细胞亚群,它们可以在受控刺激条件下从原始的CD4+前体细胞中产生。还描述了功能不同的CD8+效应器T细胞的相似亚群。虽然这一领域的早期研究表明,效应器T细胞的分化与个体发育过程中的末端分化过程类似,但最近的证据表明,T细胞效应器亚群的分化状态更具可塑性。不仅一些T细胞表现出 同时观察到多个效应器谱系的特征,但也观察到在应答过程中更多的CD4+和CD8+效应器T细胞获得新的细胞因子谱。例如,在一定条件下,CD4+Th17细胞将获得产生干扰素-γ的能力,而Th1细胞将成为分泌IL-21的Tfh细胞。这些数据表明,T细胞反应可以随着时间的推移而演变,导致在免疫反应的不同阶段占主导地位的效应器功能的变化。重要的是,这一过程可能在自身免疫反应的演变中发挥关键作用,也可能有助于慢性炎症性疾病的发病机制。我们假设转录抑制因子Blimp-1是T细胞可塑性的关键调节因子。Blimp-1在被激活的CD4+和CD8+T细胞中被包括IL-2、IL-12和IL-4在内的特定细胞因子亚群上调;因此,Blimp-1在CD4+效应Th1和Th2细胞中表达,但不在Th17细胞中表达,也在I型效应CD8+T细胞中表达。我们发现,从Blimp-1缺陷的NA和CD4+T细胞产生的Th1细胞获得了一个多谱系的分子程序,表达Th1和Th17特异性基因;在Blimp-1缺陷的CD8+T细胞感染LCMV后,基因表达也发生了类似的变化。这些数据表明,Blimp-1正常发挥抑制Th17和Tc17分化的功能,此外,效应细胞可能需要维持高度极化的I型亚群身份。为了验证这一假设,我们将首先检查Blimp的分子调控 1由不同的细胞因子转录,以确定Blimp-1在免疫反应的不同阶段的表达模式。然后,我们将确定在Th17依赖型自身免疫性疾病的发展过程中和在病毒感染期间,Blimp-1和/或Bcl-6的分级表达是否调节I型和17型效应细胞的分化。最后,我们将确定是否需要持续表达Blimp-1来维持I型谱系身份,以及在效应器T细胞中有条件地删除Blimp-1是否改变其效应器功能,并促进其诱导自身免疫的能力。总之,这些研究将确定Blimp-1表达的幅度和持续时间是否对维持T细胞分化状态至关重要,以及免疫反应期间Blimp-1表达的变化是否有助于效应器功能的可塑性。这些数据将为 致病T细胞反应引起自身免疫和其他疾病的机制。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

LESLIE JOAN BERG其他文献

LESLIE JOAN BERG的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('LESLIE JOAN BERG', 18)}}的其他基金

TCR signaling control of thymic Treg selection and immune homeostasis
TCR 信号控制胸腺 Treg 选择和免疫稳态
  • 批准号:
    10531600
  • 财政年份:
    2019
  • 资助金额:
    $ 39.11万
  • 项目类别:
TCR signaling control of thymic Treg selection and immune homeostasis
TCR 信号控制胸腺 Treg 选择和免疫稳态
  • 批准号:
    10307579
  • 财政年份:
    2019
  • 资助金额:
    $ 39.11万
  • 项目类别:
TCR signaling control of thymic Treg selection and immune homeostasis
TCR 信号控制胸腺 Treg 选择和免疫稳态
  • 批准号:
    10064991
  • 财政年份:
    2019
  • 资助金额:
    $ 39.11万
  • 项目类别:
TCR signaling control of thymic Treg selection and immune homeostasis
TCR 信号控制胸腺 Treg 选择和免疫稳态
  • 批准号:
    9887472
  • 财政年份:
    2019
  • 资助金额:
    $ 39.11万
  • 项目类别:
Dissecting the pathways controlling tunable responses to TCR signaling
剖析控制 TCR 信号传导可调反应的途径
  • 批准号:
    10074912
  • 财政年份:
    2018
  • 资助金额:
    $ 39.11万
  • 项目类别:
Dissecting the pathways controlling tunable responses to TCR signaling
剖析控制 TCR 信号传导可调反应的途径
  • 批准号:
    10314045
  • 财政年份:
    2018
  • 资助金额:
    $ 39.11万
  • 项目类别:
Plasticity of T helper cell differentiation
T辅助细胞分化的可塑性
  • 批准号:
    8664794
  • 财政年份:
    2013
  • 资助金额:
    $ 39.11万
  • 项目类别:
Plasticity of T helper cell differentiation
T辅助细胞分化的可塑性
  • 批准号:
    8833242
  • 财政年份:
    2013
  • 资助金额:
    $ 39.11万
  • 项目类别:
Regulation of conventional versus innate CD8+ T cell development
常规与先天 CD8 T 细胞发育的调节
  • 批准号:
    8317595
  • 财政年份:
    2011
  • 资助金额:
    $ 39.11万
  • 项目类别:
Regulation of conventional versus innate CD8+ T cell development
常规与先天 CD8 T 细胞发育的调节
  • 批准号:
    8190000
  • 财政年份:
    2011
  • 资助金额:
    $ 39.11万
  • 项目类别:

相似海外基金

Linkage of HIV amino acid variants to protective host alleles at CHD1L and HLA class I loci in an African population
非洲人群中 HIV 氨基酸变异与 CHD1L 和 HLA I 类基因座的保护性宿主等位基因的关联
  • 批准号:
    502556
  • 财政年份:
    2024
  • 资助金额:
    $ 39.11万
  • 项目类别:
Olfactory Epithelium Responses to Human APOE Alleles
嗅觉上皮对人类 APOE 等位基因的反应
  • 批准号:
    10659303
  • 财政年份:
    2023
  • 资助金额:
    $ 39.11万
  • 项目类别:
Deeply analyzing MHC class I-restricted peptide presentation mechanistics across alleles, pathways, and disease coupled with TCR discovery/characterization
深入分析跨等位基因、通路和疾病的 MHC I 类限制性肽呈递机制以及 TCR 发现/表征
  • 批准号:
    10674405
  • 财政年份:
    2023
  • 资助金额:
    $ 39.11万
  • 项目类别:
An off-the-shelf tumor cell vaccine with HLA-matching alleles for the personalized treatment of advanced solid tumors
具有 HLA 匹配等位基因的现成肿瘤细胞疫苗,用于晚期实体瘤的个性化治疗
  • 批准号:
    10758772
  • 财政年份:
    2023
  • 资助金额:
    $ 39.11万
  • 项目类别:
Identifying genetic variants that modify the effect size of ApoE alleles on late-onset Alzheimer's disease risk
识别改变 ApoE 等位基因对迟发性阿尔茨海默病风险影响大小的遗传变异
  • 批准号:
    10676499
  • 财政年份:
    2023
  • 资助金额:
    $ 39.11万
  • 项目类别:
New statistical approaches to mapping the functional impact of HLA alleles in multimodal complex disease datasets
绘制多模式复杂疾病数据集中 HLA 等位基因功能影响的新统计方法
  • 批准号:
    2748611
  • 财政年份:
    2022
  • 资助金额:
    $ 39.11万
  • 项目类别:
    Studentship
Recessive lethal alleles linked to seed abortion and their effect on fruit development in blueberries
与种子败育相关的隐性致死等位基因及其对蓝莓果实发育的影响
  • 批准号:
    22K05630
  • 财政年份:
    2022
  • 资助金额:
    $ 39.11万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Genome and epigenome editing of induced pluripotent stem cells for investigating osteoarthritis risk alleles
诱导多能干细胞的基因组和表观基因组编辑用于研究骨关节炎风险等位基因
  • 批准号:
    10532032
  • 财政年份:
    2022
  • 资助金额:
    $ 39.11万
  • 项目类别:
Investigating the Effect of APOE Alleles on Neuro-Immunity of Human Brain Borders in Normal Aging and Alzheimer's Disease Using Single-Cell Multi-Omics and In Vitro Organoids
使用单细胞多组学和体外类器官研究 APOE 等位基因对正常衰老和阿尔茨海默病中人脑边界神经免疫的影响
  • 批准号:
    10525070
  • 财政年份:
    2022
  • 资助金额:
    $ 39.11万
  • 项目类别:
Leveraging the Evolutionary History to Improve Identification of Trait-Associated Alleles and Risk Stratification Models in Native Hawaiians
利用进化历史来改进夏威夷原住民性状相关等位基因的识别和风险分层模型
  • 批准号:
    10689017
  • 财政年份:
    2022
  • 资助金额:
    $ 39.11万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了